DMSO-Free Cryoprotectant harnessing nature and technology
Magnus® provides key elements ideal for bone graft formation:
- An osteoconductive three-dimensional scaffold with cortical and cancellous components.
- A demineralized bone scaffold with osteoinductive potential.
Does Particle Size Make a Difference?
100-300 μm optimized particle size for bone regeneration has been shown to support direct ossification, with defect healing rates comparable to autograft.
Post-Thaw Cell Characterization
Flow cytometry analysis of the cells post-thaw reveals a unique cell population optimal for osteogenic supplementation, evidenced by high expression of MSC and pluripotent cell markers.
| CELL SURFACE MAKER | CELL TYPE | EXPRESSION |
|---|---|---|
| CD73 | MSCs | + |
| CD90 | MSCs | + |
| SSEA-4 | MSCs, Pluripotent Cells | ++ |
| CD15 | Pluripotent Cells | +++ |
| CD45 | Hemapoietic Stem Cells | - |
| GlycoA | Red Blood Cells | - |
| CD34 | Hemapoietic Stem Cells | - |
Cell Preservation: A Different Approach
DMSO-free cryoprotectant coats the cells to prevent crystalline damage.
2.5% DMSO Media Sample
Industry standard DMSO penetrates and dehydrates the cell from within to prevent crystal formation. At room temperature, DMSO-based cryoprotectants raise concerns about cytotoxicity and negative effects on cell differentiation.
Cell Preservation: A Different Approach
MIS-TLIF study demonstrated 96% fusion at 12 months.
TLIF FUSION with Allograft >
It All Adds Up To:
- A natural scaffold that provides an optimal microenvironment for osteogenesis.
- A proprietary DMSO-free cryoprotectant that allows for consistent delivery of allograft to the patient.
- A unique cell population optimal for osteogenic supplementation confirmed through flow cytometry analysis.
It All Adds Up To:
- No rinsing or decanting steps required
- Minimum of 150,000 cells per cc of allograft
Midfoot Arthrodesis: Patient with Multiple Comorbidities
12-week post-operative X-rays show complete osseous consolidation of the arthrodesis sites and no pain or swelling with palpation or manipulation of the surgical sites.
Magnus® Allograft Robust, fibrous moldability
Cortical shavings, crushed cancellous chips, and demineralized cortical bone microparticulate scaffold blend with bone gel mixture Hydrophobic properties make it more resistant to lavage.
Available Sizes
- SIZECODE
- 1 cc MG-01
- 2.5 ccMG-25
- 5.5 ccMG-5
- 10 ccMG-10
REFERENCES
- Malinin, T.I., et. al., Particulate bone allograft incorporation in regeneration of osseous defects; importance of particle sizes. The Open Orthopeadics Journal, 2007. 1:19-24
- Best, Benjamin. P. Cryprotectant Toxicity: Facts, Issues, and Questions. Rejuvenation Research, 2015. Vol. 18, No.5.
- Renzi, S., et al., Mesenchymal stromal cell cryopreservation. Biopreservation and Biobanking, 2012. 10(3): p. 276-281. Asghar, W., et al., Preserving human cells for regenerative, reproductive, and transfusion medicine. Biotechnology Journal, 2014. 9: p. 895-903.
4. Data on file at Vivex Biomedical, Inc.
5. Tally, William C, et al., Transforaminal Lumbar Interbody Fusion with Allograft: 75 Consecutive Cases at 12-Month Follow-Up. International Journal of Spine Surgery, 2018. Vol. 12, No. 1 pp 76-84.
Explore our Entire Product Line
Autologous Advanced Biologics
Advanced Synthetics
About Royal
Royal is a pioneering leader in orthobiologic and wound care research and development. Royal’s commitment lies in delivering top-tier, innovative biologic solutions that enhance the healing process and improve patients' quality of life. Royal places patient well-being at the center of its mission, offering exceptional solutions to address a variety of complex needs.
At Royal, our mission is driven by patient-centered care, innovation and excellence, and integrity and compassion. Royal provides a comprehensive array of products tailored to meet the varied needs of the orthobiologic and wound care industry.
As a rapidly expanding force in the industry, Royal is continuously developing and launching new products and solutions that set benchmarks for quality, effectiveness, and patient outcomes. Royal’s commitment to research and innovation keeps it at the forefront of the industry, helping to shape the future of healthcare and improving lives.